These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1746911)

  • 1. Dipyridamole potentiates adriamycin cytotoxicity by a mechanism other than inhibiting nucleoside uptake.
    Kusumoto H; Maehara Y; Anai H; Kumashiro R; Sugimachi K
    Anticancer Res; 1991; 11(4):1539-42. PubMed ID: 1746911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation of adriamycin cytotoxicity by dipyridamole against HeLa cells in vitro and sarcoma 180 cells in vivo.
    Kusumoto H; Maehara Y; Anai H; Kusumoto T; Sugimachi K
    Cancer Res; 1988 Mar; 48(5):1208-12. PubMed ID: 3342401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole.
    Curtin NJ; Harris AL; Aherne GW
    Cancer Res; 1991 May; 51(9):2346-52. PubMed ID: 2015598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmentation of 5-fluorouracil cytotoxicity in human colon cancer cells by dipyridamole.
    Grem JL; Fischer PH
    Cancer Res; 1985 Jul; 45(7):2967-72. PubMed ID: 4005834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of cytotoxic effect of anticancer drugs by dipyridamole in HeLa cells in vitro.
    Kusumoto H; Maehara Y; Sakaguchi Y; Kohnoe S; Kumashiro R; Sugimachi K
    Anticancer Res; 1990; 10(6):1643-5. PubMed ID: 2285237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of 5-fluorouracil cytotoxicity by combining hyperthermia and dipyridamole in vitro.
    Maehara Y; Sakaguchi Y; Kusumoto T; Kusumoto H; Sugimachi K
    Anticancer Res; 1989; 9(4):967-9. PubMed ID: 2817823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitro.
    Marshman E; Newell DR; Calvert AH; Dickinson AM; Patel HR; Campbell FC; Curtin NJ
    Clin Cancer Res; 1998 Nov; 4(11):2895-902. PubMed ID: 9829758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Potentiated antitumor effect of methotrexate by dipyridamole].
    Cao SS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1989 Feb; 11(1):7-12. PubMed ID: 2527632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adriamycin combined with hyperthermia and dipyridamole is cytotoxic both in vitro and in vivo.
    Sakaguchi Y; Maehara Y; Emi Y; Kohnoe S; Sugimachi K
    Eur Surg Res; 1992; 24(4):249-56. PubMed ID: 1505600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity.
    Smith PG; Thomas HD; Barlow HC; Griffin RJ; Golding BT; Calvert AH; Newell DR; Curtin NJ
    Clin Cancer Res; 2001 Jul; 7(7):2105-13. PubMed ID: 11448930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha1-acid glycoprotein binding.
    Curtin NJ; Bowman KJ; Turner RN; Huang B; Loughlin PJ; Calvert AH; Golding BT; Griffin RJ; Newell DR
    Br J Cancer; 1999 Aug; 80(11):1738-46. PubMed ID: 10468290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the synergistic potentiation of etoposide, doxorubicin, and vinblastine cytotoxicity by dipyridamole.
    Howell SB; Hom D; Sanga R; Vick JS; Abramson IS
    Cancer Res; 1989 Jun; 49(12):3178-83. PubMed ID: 2720673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycine 154 of the equilibrative nucleoside transporter, hENT1, is important for nucleoside transport and for conferring sensitivity to the inhibitors nitrobenzylthioinosine, dipyridamole, and dilazep.
    SenGupta DJ; Unadkat JD
    Biochem Pharmacol; 2004 Feb; 67(3):453-8. PubMed ID: 15037197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effects of dipyridamole on growth, nucleoside incorporation, and platelet-activating capability in the U87MG and SKNMC human tumor cell lines.
    Bastida E; del Prado J; Almirall L; Jamieson GA; Ordinas A
    Cancer Res; 1985 Sep; 45(9):4048-52. PubMed ID: 2992771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined treatment of adriamycin and dipyridamole inhibits lung metastasis of B16 melanoma cells in mice.
    Sakaguchi Y; Emi Y; Maehara Y; Kohnoe S; Sugimachi K
    Eur Surg Res; 1990; 22(4):213-8. PubMed ID: 2265656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole.
    Desai PB; Duan J; Sridhar R; Damle BD
    Methods Find Exp Clin Pharmacol; 1997 May; 19(4):231-9. PubMed ID: 9228648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temperature dependence studies of adriamycin uptake and cytotoxicity.
    Lane P; Vichi P; Bain DL; Tritton TR
    Cancer Res; 1987 Aug; 47(15):4038-42. PubMed ID: 3607749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity of nucleoside transport in mammalian cells. Two types of transport activity in L1210 and other cultured neoplastic cells.
    Belt JA
    Mol Pharmacol; 1983 Nov; 24(3):479-84. PubMed ID: 6314117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport.
    Smith PG; Marshman E; Newell DR; Curtin NJ
    Br J Cancer; 2000 Feb; 82(4):924-30. PubMed ID: 10732767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipyridamole reverses the resistance to topoisomerase II inhibitors but not to antimicrotubule agents in multidrug-resistant melanoma cells.
    Damle B; Desai P
    Oncol Res; 1994; 6(2):49-57. PubMed ID: 7949465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.